Business Context and Reporting Period
Purple Biotech Ltd. (Purple Biotech) filed this Form 6-K on April 22, 2025, to report the results of its Annual General Meeting of Shareholders held on the same date at its offices in Rehovot, Israel. The filing details shareholder votes on director re-elections and capital structure amendments.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report and does not contain financial performance data.
Material Changes
Shareholders approved the following material changes:
- Director Re-elections: Eric Rowinsky, Robert Gagnon, and Ido Agmon were re-elected as first-class directors until the 2028 annual general meeting.
- Capital Increase: Authorized ordinary share capital was increased from 1,000,000,000 to 100,000,000,000 shares (no par value), with corresponding amendments to Article 11 of the Articles of Association.
- Rejected Proposals: Proposals 2(a) and 2(b) were not supported by shareholders.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document strictly reports the outcomes of the shareholder vote.
Key Facts for Investor Verification
- Verify the specific details of the rejected Proposals 2(a) and 2(b) in the Proxy Statement filed on February 28, 2025.
- Confirm the impact of the 100-fold increase in authorized share capital on future dilution potential.
- Review the terms of the re-elected directors' mandates extending to 2028.